Skip to main content
House user fee bill softens generic-drug competition language
7/14/2017

The latest iteration of a House bill reauthorizing the FDA's user fee program says the FDA "may" expedite review of certain competitive generic-drug applications upon request. The previous version of the bill said "shall."

Full Story: